 Collegium Pharmaceutical Inc NASDAQ: COLL updated financial guidance for FY22 to include the expected impact of the BioDelivery Sciences International Inc BDSI acquisition. Near-term, we are laser-focused on seamless integration of BDSI, maximizing the potential of. 